about
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanc...
Read More
2.92
0.07
(2.46%)
1.7M
XNAS Volume
XNAS 17 Jul, 2026 1:51 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
Altimmune Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..